Free Trial
NASDAQ:ELYM

Eliem Therapeutics (ELYM) Stock Price, News & Analysis

Eliem Therapeutics logo
$1.18 -0.02 (-1.67%)
As of 05/23/2025

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Key Stats

Today's Range
$1.17
$1.23
50-Day Range
$1.13
$1.36
52-Week Range
$2.35
$11.55
Volume
178,602 shs
Average Volume
486,688 shs
Market Capitalization
$35.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELYM Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

ELYM Stock Analysis - Frequently Asked Questions

Eliem Therapeutics' stock was trading at $1.80 at the start of the year. Since then, ELYM stock has decreased by 34.4% and is now trading at $1.18.
View the best growth stocks for 2025 here
.

Eliem Therapeutics, Inc. (NASDAQ:ELYM) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.19.

Eliem Therapeutics (ELYM) raised $75 million in an initial public offering (IPO) on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eliem Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/08/2021
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELYM
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.12 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
0.30

Miscellaneous

Free Float
28,354,000
Market Cap
$35.11 million
Optionable
Not Optionable
Beta
-0.39
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ELYM) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners